3M Drug Delivery to Manufacture Transdermal Patch in Europe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

3M Drug Delivery to Manufacture Transdermal Patch in Europe



The specialty pharmaceutical company ProStrakan Group has received approval from EMA to market Sancuso (granisetron transdermal system) in the European Union, with 3M Drug Delivery Systems acting as the manufacturer. ProStrakan began marketing the product in October 2013 in the United Kingdom, Germany, and the Netherlands. Additional European countries are expected to be added in 2014.

Initially introduced in the United States in 2008, Sancuso is used to treat chemotherapy-induced nausea and vomiting. The transdermal patch is applied to the upper arm and can be worn for seven days, providing continuous transdermal delivery and eliminating the need to take pills daily to control nausea and vomiting.

ProStrakan previously relied on a different manufacturer for the US supply of Sancuso. FDA approval is currently pending for the 3M Drug Delivery Systems manufactured product.

Source: 3M Drug Delivery Systems

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here